Academic Journal
Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety.
| Τίτλος: | Durvalumab Consolidation After Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Efficacy and Safety. |
|---|---|
| Συγγραφείς: | Musheer A; Department of Internal Medicine, Dow Medical College, DUHS, Karachi., Mannan MS; Department of Internal Medicine, Marshfield Clinic, Marshfield, WI., Khan MW; Department of Internal Medicine, Medical University of South Carolina, SC., Junaid A; Department of Internal Medicine, Dow Medical College, DUHS, Karachi., Basit T; Department of Internal Medicine, Dow Medical College, DUHS, Karachi., Hafeez AS; Department of Internal Medicine, CMH Multan Institute of Medical Sciences, Multan, Pakistan., Shahzad M; Department of Hematology/Oncology, Lee Moffitt Cancer Center and Research Institute, Tampa, FL. |
| Πηγή: | American journal of clinical oncology [Am J Clin Oncol] 2026 Aug 10. Date of Electronic Publication: 2026 Aug 10. |
| Publication Model: | Ahead of Print |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-453X (Electronic) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: New York, N.Y. : Masson Pub. USA, c1982- |
| Περίληψη: | Objectives: Durvalumab consolidation following concurrent chemoradiotherapy (CRT) has become the standard of care for patients with unresectable stage III non-small cell lung cancer (NSCLC). However, survival outcomes reported in clinical trials and real-world studies have been inconsistent, making it difficult to understand the efficacy and safety of this treatment modality fully. Our study aims to pool the available evidence to evaluate the impact of durvalumab in patients with unresectable stage III NSCLC. Methods: PubMed, Embase, Cochrane Library, and Web of Science were searched for studies including randomized controlled trials and real-world observational studies that assess durvalumab after definitive CRT in unresectable stage III NSCLC, till January 2026. Data extracted included median overall survival (OS), median progression-free survival (PFS), and survival rates. Random-effects meta-analyses were performed to pool OS and PFS. Results: A total of 3 studies comprising 861 patients with unresectable stage III NSCLC were included. Durvalumab consolidation after definitive CRT showed no statistically significant effect on OS (HR: 1.06, 95% CI: 0.52-2.14; I ²=51.6%; P =0.1268) or PFS (HR: 0.87, 95% CI: 0.45-1.68; I ²=49.6%; P =0.1374). Heterogeneity was moderate for both outcomes. In addition to these primary outcomes, multiple secondary efficacy and safety outcomes were systematically evaluated, including overall response rate and treatment-related adverse effects. Conclusions: Durvalumab consolidation demonstrates a favorable safety profile, but outcomes remain variable across studies. These findings highlight the importance of biomarker-driven patient selection and prospective real-world evaluation to maximize the clinical benefit of durvalumab in unresectable stage III NSCLC. (Copyright © 2026 Wolters Kluwer Health, LLC. All rights reserved.) |
| Competing Interests: | The authors declare no conflicts of interest. |
| References: | Garg P, Singhal S, Kulkarni P, et al. Advances in non-small cell lung cancer: current insights and future directions. J Clin Med. 2024;13:4189. Kim F, Borgeaud M, Addeo A, et al. Management of stage III non-small-cell lung cancer: rays of hope. Explor Target Anti-Tumor Ther. 2024;5:85–95. Bortolot M, Cortiula F, Fasola G, et al. Treatment of unresectable stage III non-small cell lung cancer for patients who are under-represented in clinical trials. Cancer Treat Rev. 2024;129:102797. Mooradian MJ, Cai L, Wang A, et al. Durvalumab after chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer. JAMA Netw Open. 2024;7:e247542. Verfaillie S, Lambrecht M, Berkovic P, et al. Treatment of unresectable stage III NSCLC: real world cohort study and literature review. Cancer Treat Res Commun. 2023;36:100727. Ma J, Jiang J. Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (Review). Oncol Lett. 2026;31:46. Nortey-Adom EE, Abraham IC, Karbo SA, et al. Durvalumab as consolidation therapy in non-small cell lung cancer: efficacy, safety, and long-term outcomes. Int J Surg Glob Health. 2026;9. doi:10.1097/GH9.0000000000000594. (PMID: 10.1097/GH9.0000000000000594) Morgan C, Kurland J, Patel M, et al. Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers. J Immunother Cancer. 2025;13:e011140. Delcuratolo MD, Crespi V, Saba G, et al. The evolving landscape of stage III unresectable non-small cell lung cancer “between lights and shadows”. Cancer Treat Rev. 2025;135:102918. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919–1929. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. Wu YL, Wu L, Bi N, et al. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. J Hematol OncolJ Hematol Oncol. 2025;18:111. Bradley JD, Sugawara S, Lee KH, et al. Simultaneous durvalumab and platinum-based chemoradiotherapy in unresectable stage III non–small cell lung cancer: the phase III PACIFIC-2 study. J Clin Oncol. 2025;43:3610–3621. Stevens S, Nindra U, Shahnam A, et al. Real world efficacy and toxicity of consolidation durvalumab following chemoradiotherapy in older Australian patients with unresectable stage III non-small cell lung cancer. J Geriatr Oncol. 2024;15:101705. Garassino MC, Khalifa J, Reck M, et al. Durvalumab after sequential chemoradiotherapy in unresectable stage III non-small-cell lung cancer—final analysis from the phase II PACIFIC-6 trial. ESMO Open. 2025;10:105071. Wheatley-Price P, Navani V, Pabani A, et al. Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study. Lung Cancer. 2025;204:108583. Girard N, Bar J, Garrido P, et al. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18:181–193. Mouri A, Kisohara A, Morita R, et al. A phase II study of daily carboplatin plus irradiation followed by durvalumab therapy for older adults (≥75 years) with unresectable III non-small-cell lung cancer and performance status of 2: NEJ039A. ESMO Open. 2024;9:103939. Gómez Rueda A, Taus Á, Álvarez Álvarez R, et al. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clin Transl Oncol. 2024;26:1779–1789. Nakamichi S, Kubota K, Misumi T, et al. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 (DATE Study). Clin Cancer Res. 2024;30:1104–1110. Al-Salama ZT. Durvalumab: a review in extensive-stage SCLC. Target Oncol. 2021;16:857–864. Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–741. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1:1325–1332. Wu L, Zhang Z, Bai M, et al. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations. Cell Commun Signal CCS. 2023;21:119. Pevzner AM, Tsyganov MM, Ibragimova MK, et al. Abscopal effect in the radio and immunotherapy. Radiat Oncol J. 2021;39:247–253. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–2350. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:1301–1311. Shaverdian N, Offin MD, Rimner A, et al. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;144:101–104. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–1550. Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC-an update from the PACIFIC trial. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2021;16:860–867. So WV, Dejardin D, Rossmann E, et al. Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. J Immunother Cancer. 2023;11:e006464. Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2019;35:329. Voong KR, Hazell SZ, Fu W, et al. Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 2019;20:e470–e479. |
| Contributed Indexing: | Keywords: NSCLC; checkpoint inhibitor; chemoradiotherapy; durvalumab; stage III; unresectable |
| Entry Date(s): | Date Created: 20260810 Latest Revision: 20260928 |
| Update Code: | 20260929 |
| DOI: | 10.1097/COC.0000000000001361 |
| PMID: | 42574292 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1537-453X |
|---|---|
| DOI: | 10.1097/COC.0000000000001361 |